alternative strategy of inhibiting DPP-IV activity, we generated a panel of tight binding inhibitory mouse monoclonal antibodies (mAbs) against rat DPP-IV. When tested in vitro, these mAbs partially inhibited the GLP-1 cleavage activity of purified enzyme and rat plasma. To understand the partial inhibition, we solved the co-crystal structure of one of mAb Fabs (Ab1) in complex with rat DPP-IV. While Ab1 doesn't bind at the active site, it partially blocks the side opening, which prevents the large substrates such as GLP-1 from accessing the active site, but not small molecules such as sitagliptin. When Ab1 was tested in vivo, it reduced plasma glucose and increased plasma GLP-1 concentration during an oral glucose tolerance test in rat. Together, we demonstrated the feasibility of using mAbs to inhibit DPP-IV activity and to improve glucose tolerance in a diabetic rat model.
INTRODUCTION
Serine protease dipeptidyl peptidase IV (DPP-IV) (also referred to as CD26) is a type II membrane protein that modulates biological activities of peptide hormones, cytokines, and neuropeptides by removing two residues from the N-termini of these peptides (1) (2) (3) . DPP-IV is well conserved across species. Human DPP-IV shares 85% sequence identity with rat DPP-IV (3, 4) . Membrane-bound DPP-IV functions as a peptidase as well as binding partner for other proteins, such as adenosine deaminase (ADA) and T-cell antigen (CD45), and is involved in T-cell co-stimulation and tumor suppression (4, 5) . DPP-IV also exists in soluble form (residues 39-766) in plasma as result of a proteolysis near the N-terminal transmembrane domain (6) .
Soluble and membrane-bound forms of DPP-IV have similar catalytic activities. In vivo, DPP-IV proteins are heavily glycosylated and exist as homo-dimers, where each subunit is comprised of two structural domains: the  hydrolase and -propeller domains (4) . The catalytic site is located in a large cavity formed between these two domains. There are two structural holes in DPP-IV that could serve as substrate access and product discharge routes for catalysis: a tunnel through the -propeller domain (propeller opening) and a side opening formed between the interface of the -propeller domain and catalytic domain (7) (8) (9) (10) .
Suppression of DPP-IV activity is an established strategy to treat type 2 diabetes mellitus, which is a chronic disease characterized by elevated blood glucose levels and attenuated response to insulin (11) (12) (13) (14) . DPP-IV inactivates incretins, especially GLP-1 and GIP which are released from the gut during meals and serve as enhancers of glucose-dependent insulin release from pancreatic -cells (15). Because of DPP-IV activity and the small sizes of GLP-1 and GIP, their half-lives are less than 1 minute. Several therapeutic strategies, including administration of exogenous GLP-1, or DPP-IV-resistant GLP-1 analogues and inhibition of DPP-IV with small molecule inhibitors have been explored as potential treatments for type 2 diabetes (12, (16) (17) (18) (19) . To date, a few GLP-1 analogues and a number of small molecule DPP-IV inhibitors have become marketed products or are at different stages of clinical development.
Currently, five small molecule DPP-IV inhibitors have been approved as anti-hyperglycemic drugs for type 2 diabetes. They are linagliptin, sitagliptin, vildagliptin, saxagliptin and alogliptin (13, 20, 21) . In humans, the approved compounds are generally well tolerated and demonstrate various degrees of efficacy in treating type 2 diabetes at recommended doses, suggesting that inhibition of DPP-IV activity represents a desirable therapeutic approach for type 2 diabetes (13, (22) (23) (24) (25) . However, adverse effects such as nausea, common cold-like symptoms and pancreatitis have been reported for approved DPP-IV inhibitors (25) . Most of the small molecules are competitive reversible inhibitors, with different degrees of selectivity towards other family members of prolyl peptidases such as DPP-VIII and DPP-IX. These inhibitors have been implicated in preclinical toxicity, including suppression of T-cell activation and proliferation in some studies (26) .
Antibodies have been widely used as therapeutic agents for a variety of diseases (27, 28) . In general, they function to modulate receptor activity, neutralize soluble ligands, and deliver cytotoxic compounds to target tissues. Antibodies have excellent attributes as pharmacologic agents because of their high specificities and long in vivo half-lives. Proteases generally have a cavity in the catalytic site that accommodates substrates and cleaves the substrate peptide bonds. Previously, highly selective inhibitory antibodies have been identified for proteases with one structural opening for substrates (29) (30) (31) . These antibodies interact directly with loops near the substrate-binding site thus blocking substrates from accessing the active site. Here we describe identification of an inhibitory antibody against DPP-IV that improves glucose tolerance and plasma GLP-1 concentrations in a rat diabetic model. Through this antibody, we demonstrated that an inhibitory antibody for DPP-IV could be used to raise plasma GLP-1 concentration and improve glucose tolerance in a rat diabetic model, thus affirming the plausibility of using a DPP-IV inhibitory antibody as a therapy for type 2 diabetes.
EXPERIMENTAL PROCEDURES
Rat DPP-IV and DPP-IV activity assays cDNA of rat DPP-IV (residues 37-767) was fused at the 3' end to a sequence encoding a C-terminal His8 tag and at the 5' end to a sequence coding for an IgG kappa light chain signal peptide. This rat DPP-IV construct was transiently expressed in 293 6E cells. Conditioned media, which contained secreted soluble DPP-IV, was harvested and DPP-IV proteins were purified using affinity chromatography (AF) followed by size exclusion chromatography (SEC).
In the AF step, conditioned media was concentrated and buffer exchanged against 20 mM Tris-HCl, pH 7.9, 1 M NaCl and 20 mM imidazole. Rat DPP-IV was captured on a Ni-IMAC column, and non-specific interactions were removed by washing with the binding buffer. Rat DPP-IV was recovered by eluting with 250 mM imidazole in 20 mM TrisHCl, pH 7.3, 0.5 M NaCl. The recovered rat DPP-IV was polished on a Superdex 200 SEC column and formulated in 25 mM HEPES, pH 7.6, 150 mM NaCl.
DPP-IV's dipeptidyl-peptidase activity was monitored by cleavage of a peptide substrate GPpNA. In the reaction, DPP-IV was used to cleave 1 mM substrate in PBS. Cleavage of GP-pNA was monitored by A405nm.
GLP-1 degradation and DPP-IV inhibition assays
Proteolytic cleavage of GLP-1 (residues 7-36) to GLP-1 (residues 9-36) by recombinant DPP-IV was monitored using alpha screening and HPLC assays. In the alpha screening assay, Cterminal biotinylated GLP-1 (residues 7-36) was cleaved by recombinant DPP-IV. At specific time points, an aliquot of reaction mix was quenched by adding sitagliptin to a final concentration of 1 uM; and the amount of intact C-terminal biotinylated GLP-1 (residues 7-36) was quantitated by alphascreening with a steptavidin-coated donor bead and GLP-1 (residues 7-36) specific Ab coated acceptor beads. In the HPLC assay, 12 uM GLP-1 C-terminal amide was cleaved by 1.78 nM recombinant rat DPP-IV in PBS containing 0.1% BSA. At each time point, 40 ul of reaction mix was withdrawn and the reaction was stopped by adding 60 ul of 8 M guanidine-HCl/0.5% TCA. Substrate, GLP-1 (residues 7-36), and product, GLP-1 (residues 9-36), were resolved on a Jupiter C18 column (2.1 mm x 150 mm) with an acetonitrile gradient of 32%-45% that contained 0.1% TFA in 6 minutes at a flow rate of 0.3 ml/min. Integration of chromatogram A280nm peak area was used to quantitate the amount of GLP-1.
Inhibition of DPP-IV by monoclonal DPP-IV antibodies was analyzed by measuring the GLP-1 cleaving activity of rat DPP-IV proteins in the presence of increasing amounts of mAbs. In Figure 1A , rat DPP-IV was incubated for 60 min with mAbs against rat DPP-IV or control mAb. The reaction was started by adding GLP-1(residues 7-36) and reaction buffer to bring the final concentrations of GLP-1 and rat DPP-IV to 12 uM and 1.78 nM respectively in a 40 ul reaction volume. Twenty three minutes after adding GLP-1, the reactions were stopped by adding 60 ul 8 M guanidine-HCl in 0.5% trichloroacetic acid (TCA) to bring the volume to 100 ul. Reaction samples were analyzed on C18 RP-HPLC and concentrations of GLP-1 (residues 7-36) and GLP-1 (residues 9-36) were estimated from integrated A280nm peak areas of GLP-1 peaks.
Vi is calculated as product (GLP-1 (residues 9-36)) accumulating rate (nM/min) in the presence of mAb. V0 is product accumulating rate (nM/min) in the absence of any mAb. Vi/V0% represents degree of inhibition of DPP-IV by mAbs. In Figure 1B Substrate GLP-1 (residues 7-36) and product GLP-1 (residues 9-36) were quantitated by HPLC analysis that monitored FAM fluorescence (ex = 495nm, em = 517 nm) on a Jupiter C4 column. Degree of inhibition (Vi/V0%) and IC 50 were calculated similarly as in Figure 1 (Panel B)
Antibody generation and characterization
Monoclonal antibodies against rat DPP-IV were generated by immunizing C57BL/6 mice with purified soluble rat DPP-IV transiently expressed in 293 6E cells. B cells from immunized mice were harvested and fused to a non-secretory mouse myeloma cell line Sp2/0-Ag14 (ATCC, Manassas, VA) to generate hybridomas using standard techniques. Conditioned media from hybridoma clones were first screened for rat DPP-IV binding activity by ELISA using biotinylated rat DPP-IV as the capture antigen, followed by characterization of DPP-IV inhibitory activity using the alpha-screening method. Positive clones that showed inhibitory activity against DPP-IV in alpha screening were further characterized using the HPLC-based inhibition assays described above.
Competition ELISA was used to group the inhibitory mAb clones. Monoclonal antibodies against rat DPP-IV were coated on the ELISA plate surface and used to capture biotinylated rat DPP-IV. Captured DPP-IV was detected with HRP-labeled streptavidin. To group the positive mAbs, mAb-coated ELISA plates were used to capture biotinylated rat DPP-IV that was preincubated with other individual mAbs. When two mAbs are in the same epitope bin, the signal of DPP-IV in the competition ELISA is decreased.
Monoclonal antibodies were expressed and purified as previously described (32) . Briefly, mAbs were expressed in 293 6E cells or in hybridoma clones. Expressed mAbs were secreted into conditioned media and captured on MabSelect SuRe columns, which had been equilibrated with Tris or HEPES buffered saline solutions (TBS or HBS). After washing with TBS or HBS, bound IgG proteins were eluted with 0.5% acetic acid, pH 3.5. Eluted IgG molecules were further polished on SP-Sepharose or Superdex 200 to remove aggregates. The Ab1 Fab fragment was prepared by digesting full antibody molecules with immobilized papain (Thermo Scientific) according to the manufacturer's instructions. The Fab molecules were recovered by passing through a MabSelect SuRe column for Fc fragment removal, and were formulated in 10 mM acetate buffer solution pH 5.2, 150 mM NaCl using dialysis.
Binding affinity Binding of mAb to rat DPP-IV proteins was measured using the KinExa 3000 (Sapidyne Instruments) and ForteBio Protein G chip on Octet96 according to manufactures' recommendations and as previously described for analyzing mAb-antigen interactions (32) . In Octet96 analysis, Ab1 at 300 ug/ml first bound to Protein G tip in HBS. Then Ab1 on the Protein G tip was used to bind to rat DPP-IV or control proteins in HBS or in 293 cell lysate (2 mg/ml in HBS) ( Figure S1 ).
X-ray crystallography
The purified DPP-IV/Ab1 Fab complex was concentrated to 7 mg/ml in 20 mM Tris pH 7.9, 200 mM NaCl. Crystals were grown at 20 ºC in sitting drops with 1.5 ul protein solution plus 1.5 ul reservoir solution of 2.2 to 2.7 M ammonium sulfate in Tris buffer, pH 7.5 to 9.0. To obtain the ternary complex of DPP-IV/Ab1/a small molecule inhibitor (sitagliptin), purified DPP-IV/Fab complex at 7 mg/ml was incubated with sitagliptin at 0.3 mM for two to three hours before crystallization. For X-ray diffraction data collection, crystals were transferred into well solution with 20% (w/v) of ethylene glycol and flash frozen in liquid nitrogen.
The X-ray diffraction data were collected at the synchrotron beamline 502 at Advanced Light Source (ALS) (Berkeley, CA), and processed with program MOSFLM (33) and SCALA (34) in the CCP4 program suite (35) . The structure was solved to a resolution of 2.5 Å by molecular replacement method MOLREP (36) using a previously published human DPP-IV structure (PDB code: 2OGZ) (37)) as a search model for DPP-IV, and a Fab structure (PDB code: 1A6T) (38) as a search model for Ab1. Model building and refinement were carried out in COOT (39) and REFMAC (40) in CCP4, respectively (Table S1 ). All structural figures were prepared using Pymol (http://www.pymol.org).
Studies in rat models Zucker fatty rats were fed with 11% breeder chow. In an oral glucose tolerance test, 4 hour-fasted male Zucker fatty rats (13-14 week, HAR) were intravenously dosed with anti-DPP-IV (20mg/kg) or IgG control (20mg/kg) at -90 min, followed by oral gavage of sitagliptin (30mg/kg) at -40 min. We used a high dose of Ab1 and sitagliptin to promote complex formation of DPP-IV/Ab1 and DPP-IV/sitagliptin in our initial animal efficacy study. At time zero, animals were orally administered with 2g/kg glucose. Blood glucose levels were measured at -90, 0, 10, 30, 60, 90, and 120 minutes by glucose strip. Blood samples were collected at -90, 0, 10, 30, 60 minutes and GLP-1 and insulin concentrations were measured using a GLP-1 quantitation kit from Linco and a rat insulin quantitation kit from Alpco.
RESULTS

Generation of inhibitory antibodies against rat DPP-IV
C57BL/6 mice were immunized with dimeric rat DPP-IV. B cells from immunized mice were fused to non-secretory myeloma cells to generate hybridomas. Approximately 2900 antibody clones that bind rat DPP-IV were identified by ELISA screening with purified rat DPP-IV protein as the capturing agent. From these clones, 13 were selected based on their inhibitory activity in the GLP-1 degradation alpha screening assay. These 13 antibodies were grouped into three noncompeting bins based on competition ELISA assay.
Identification of specific high-affinity partial inhibitory antibodies
Affinities of mAbs representing each of the three epitope bins (Ab1, Ab2 and Ab3) were analyzed in a KinExa-based solution equilibriumbinding assay using purified rat DPP-IV dimers as antigens. The affinities for rat DPP-IV are around 10 pM, 7.5 pM, and 117 pM for Ab1, Ab2 and Ab3, respectively (Table 1) . Whereas Ab1 binds to rat DPP-IV with high affinity, it shows minimum binding for human DPP-IV and DPP-IX, bovine serum albumin and proteins in 293 cell lysate ( Figure S1 ).
All 13 mAbs from the three bins were tested for inhibitory activity towards rat DPP-IV. When small chromogenic peptides (GP-pNA) were used as substrates, none of the 13 antibodies inhibited DPP-IV activity ( Figure S2 and unpublished data) . To confirm and assess the inhibitory activities observed in the alpha screening assay, we performed a more quantitative HPLC assay using GLP-1 as a substrate ( Figure 1A ). Non-binding control mAb or non-inhibitory rat DPP-IV binder clone (Ab10) showed no inhibitory activity against DPP-IV-mediated cleavage of GLP-1 ( Figure 1A) . In constrast, all putative inhibitory mAbs demonstrated inhibition of DPP-IV activity by 60-80% at saturating antibody concentrations, suggesting that these mAbs are partial inhibitors. The top three candidates, i.e., Ab1, Ab2 and Ab3, displayed IC 50 values of 0.79, 0.6 and 1.02 nM, respectively ( Figure 1B) . These values approach half of the DPP-IV concentration used in the assay, indicating the tight affinity nature of the bindings. The tight binding affinities of these inhibitory mAbs agreed with the K d results obtained from affinity measurement.
To further confirm the mAb's ability to inhibit DPP-IV activity under more physiological conditions, we analyzed the effects of Ab1 and Ab2 on GLP-1 cleaving activity in rat plasma (Figure 2) . Results from this experiment indicated that Ab1 and Ab2 inhibited the conversion of FAM-labeled GLP-1(residues 7-36) (substrate) to GLP-1(residues 9-36) (product) at IC 50 of 6.8 and 5.9 nM, respectively.
Likewise, the two antibodies only partially inhibited plasma's GLP-1 degrading activity by 45% at the condition used. The data confirms the partial inhibitory activity of Ab1 and Ab2 for endogenous DPP-IV in rat plasma.
Structural elucidation of partial inhibition by Ab1
To elucidate the molecular mechanism of partial inhibition of these mAbs, we solved the Xray co-crystal structure of DPP-IV in complex with Ab1 Fab. The binary complex structure was determined to a resolution of 2.4 Å in a space group of P2 1 with two copies of the complex in an asymmetrical unit. Overall, the structure is well ordered except for the constant domains of Fab which are highly flexible.
The structure of DPP-IV/Ab1 Fab complex reveals a homodimer of DPP-IV proteins with each monomer binding one Fab molecule ( Figure  3A) . The DPP-IV dimer is nearly identical to the previously reported apo structure of rat DPP-IV (PDB code: 2GBC) (41) with an rmsd of 0.47 Å for 1300 C atoms from the dimer. Each DPP-IV monomer adopts a two-domain architecture of Nterminal 8-blade -propeller and C-terminal catalytic  hydrolase fold. The active site is located in the large central cavity which contains two openings to the outside. The propeller opening, located in the center of the -propeller domain, has a pore size of about 9 x 16 Å ( Figure  3B ). The side opening between the N-and Cterminal domains is rather large with a dimension of about 16 x 22 Å ( Figure 3B ). The distances from the active site to the protein surface are approximately 20 and 35 Å through the side opening and the propeller opening, respectively. Due to the size difference of these two openings, it is suggested that the side opening serves as the entrance path for the substrates and the propeller/side opening as the exit route (7-10).
Ab1 Fab binds to the side of the-propeller domain of DPP-IV. The recognition of Ab1 is mediated mainly by three CDR loops in the heavy chain and CDR loop 3 in the light chain ( Figure  3C ). The key epitope on DPP-IV is located in the linker region between blade 1 and blade 2 of the -propeller, with amino acid sequence of 89 ENSTFEIFGD 98 , in which Glu94 and Ile95 make close van der Waals interactions with the Fab of Ab1 ( Figure 3D) . Interestingly, the corresponding sequence for human DPP-IV in this region is 91 ENSTFDEFGH 100 ( Figure S1B ). The mutation of the critical epitope residues Glu94 and Ile95 in rat DPP-IV to Asp96 and Glu97 in human protein rationalizes the lack of cross reactivity of Ab1 to human DPP-IV and Ab1's high specificity.
As the heavy chain of the CDR region of Ab1 plays a major role in epitope recognition to DPP-IV, the light chain CDR loops are situated at the side opening. Due to the large size of this side aperture, however, Ab1 Fab does not block this opening completely, leaving enough space for smaller substances but not large substrates to access the catalytic site ( Figure 3E ). To confirm this structural observation, we co-crystallized the substrate peptide GLP-1 or a small molecule inhibitor sitagliptin with DPP-IV/Fab complex. While the co-crystal structure of DPP-IV/Ab1 in the presence of GLP-1 shows an unoccupied active site, the ternary co-crystal structure including sitagliptin shows the inhibitor bound at the active site ( Figure 4A ). The complex structure of DPP-IV/Fab/sitagliptin reveals very little change in the binding mode of sitagliptin in comparison with the previously reported co-crystal structure of sitagliptin with human DPP-IV (PDB code: 1X70) (42) as well as the active site and Ab1 binding ( Figure 4B ). Thus, Ab1 does not blockade the DPP-IV substrate-binding site directly, instead it restricts the substrate path to the catalytic site. The structural data provides a sensible molecular basis for the observed partial inhibitory activity for these mAbs.
In vivo efficacy of Ab1
To investigate whether Ab1 could improve glucose tolerance and raise GLP-1 concentration in vivo, we tested Ab1 in a Zucker fatty rat diabetic model using sitagliptin as a positive control ( Figure 5) .
In this experiment, we observed that in OGTT analyses, Ab1 improved glucose tolerance and had similar efficacy in improving glucose tolerance as sitagliptin had ( Figure 5A ). At time points of 60 and 90 minutes post glucose challenge, Ab1 reduced glucose level from an average of 299.4 mg/DL to an average of 228.9 mg/DL with P <0.0001 (60min time point), and from an average of 287.6 mg/DL to an average of 229.8 mg/DL with P <0.01 (90 min time point). In comparison, sitagliptin reduced plasma glucose level from 299.4 mg/DL to 242.1 mg/DL with P <0.01, and from 287.6 mg/DL to 229.1 mg/DL with P <0.01 at time points of 60 and 90 minutes, respectively. The increase in glucose tolerance is accompanied by statistically significant or a visible trend of increased plasma GLP-1 and insulin concentrations ( Figures 5B and  5C ).
When plasma GLP-1 concentrations of different groups were compared ( Figure 5B ), we observed that administrating Ab1 raised plasma GLP-1 concentration, although at weaker efficacy in comparison to sitagliptin under experimental conditions. The effects of sitagliptin in increasing GLP-1 concentration were found to be statistically significant for all of the time points assayed. For Ab1, the increase in plasma GLP-1 reached statistical significance at 10 min post glucose challenge.
Furthermore, we also compared plasma insulin concentrations of different treatment groups. In comparison with glucose and GLP-1 levels, the trend of plasma insulin concentration of the Ab1 group showed nearly identical increase as that of sitagliptin, although neither reached statistical significance ( Figure 5C ). Taken together, the results from this experiment demonstrate that an inhibitory antibody for DPP-IV is capable of achieving in vivo efficacy to increase plasma GLP-1 concentration and improve glucose tolerance.
DISCUSSION
Small molecule inhibitors targeting DPP-IV enzymatic activity represent a new class of antihyperglycemic agents for treatment of type 2 diabetes (13, 20, 43) . Until now, large molecule therapies targeting DPP-IV have not been reported. Antibody-based large molecule therapies offer long in vivo half-lives and high degrees of target specificity, which generally imparts improved efficacy over small molecule drugs. Here we report the discovery of an inhibitory antibody against DPP-IV that binds to the -propeller domain of DPP-IV and partially inhibits the GLP-1 cleavage activity by impeding the substrate from accessing the catalytic site. Importantly, this antibody demonstrated its efficacy in improving glucose tolerance and raising plasma GLP-1 concentrations in a diabetic animal model.
In this study, we identified only partial inhibitory antibodies against rat DPP-IV. DPP-IV activity is involved in many functions of the metabolic, endocrine and immune systems and is implicated in regulating cell adhesion, cancer growth, and bone marrow mobilization (44) . Its physiological substrates include GIP, GLP-1, substance P (SP) and chemokines SDF1a (stromal cell-derived factor 1 a) and SDF1b (45) . SDF1 chemokines are chemo-attractants for lymphocytes and monocytes, and regulate T-and B-lymphocyte development as well as mature lymphocyte survival. SP is a neurotransmitter/ modulator and regulates nociception, pain transmission, smooth muscle contractions and anxiety/stress related responses.
It is perceivable that long-term administration of an antibody with a partial inhibitory activity may have a better safety profile than a complete inhibitory antibody by permitting a low level of DPP-IV activity to degrade its physiological substrates. Future development of a fully inhibitory antibody against DPP-IV would enable us to compare efficacy and safety profiles between complete and partial inhibitory antibodies.
Our results demonstrate the potential of using a DPP-IV inhibitory antibody to improve glucose tolerance and plasma GLP-1 concentrations in vivo. However, whether an inhibitory DPP-IV antibody can become a successful incretin drug depends on factors beyond in vivo activity, or pharmacokinetic and pharmacodymanic superiority over small molecule DPP-IV inhibitors.
A detailed investigation of efficacy, drug safety and dosing frequency is necessary to evaluate the clinical utility of inhibitory antibodies over small molecule DPP-IV inhibitors. The results observed in this report are the first step in exploring large molecule therapeutics to target DPP-IV activity and could potentially lead to an incretin agent that is long lasting, specific, and efficacious in improving type 2 diabetic symptoms in humans.
Note
Structures of DPP-IV in complex with Ab1 Fab have been deposited at RCSB Protein Data Bank under accession codes 4FFV (for DPP-IV/Fab) and 4FFW (for DPP-IV/Fab/sitagliptin). 
